CD79A&CD79B產(chǎn)品信息
英文名稱:B-cell antigen receptor complex-associated protein beta chain
中文名稱:B細(xì)胞抗原受體復(fù)合物相關(guān)蛋白β鏈
靶點別稱:CD79A&CD79B
物種:Human/Cynomolgus
屬性:Protein/Cell
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
CD79A&CD79B分子背景
CD79a和CD79b異二聚體是B細(xì)胞受體(BCR)復(fù)合物的重要信號成分,在B細(xì)胞發(fā)育和抗體產(chǎn)生中起著至關(guān)重要的作用。BCR復(fù)合物由與信號成分非共價結(jié)合的配體結(jié)合受體(膜免疫球蛋白;mIg)、CD79a(Igα)和CD79b(Igβ)的二硫鍵連接異二聚體組成。這兩種CD79亞基都由一個Ig樣結(jié)構(gòu)域、一個跨膜(TM)區(qū)域和一個較長的細(xì)胞質(zhì)尾部(CYT)組成,該尾部包含一個基于免疫受體酪氨酸的激活基序(ITAM)。
關(guān)鍵字: CD79A & CD79B;CD79A蛋白;CD79B蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。